AlphaCrest Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

AlphaCrest Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,419	Closed	-$84K	–	1359
2022 Q1	$84K	Buy	14,419 +2,919	+25%	+$17.4K	﹤0.01%	1220
2021 Q4	$86K	Buy	11,500 +968	+9%	+$8.41K	﹤0.01%	1347
2021 Q3	$95K	Sell	10,532 -23,052	-69%	-$228K	﹤0.01%	1226
2021 Q2	$402K	Buy	33,584 +15,253	+83%	+$173K	0.02%	1027
2021 Q1	$230K	Sell	18,331 -19,112	-51%	-$258K	0.01%	1101
2020 Q4	$584K	Sell	37,443 -94,141	-72%	-$1.1M	0.05%	567
2020 Q3	$1.24M	Buy	131,584 +100,584	+324%	+$1.09M	0.14%	194
2020 Q2	$278K	Buy	+31,000	New	+$288K	0.05%	667
2020 Q1	–	Sell	-10,200	Closed	-$85K	–	1250
2019 Q4	$85K	Buy	+10,200	New	+$93.8K	0.01%	1229

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AlphaCrest Capital Management's SGMO Position: Q2 2022 in Review

AlphaCrest Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2022, closing a stake of 14,419 shares — an estimated $84K sold.

AlphaCrest Capital Management first reported a position in SGMO in Q4 2019 and held it in 9 quarters. The position peaked at $1.24M in Q3 2020. 188 funds tracked by Wall St. Rank hold SGMO as of Q2 2022.

AlphaCrest Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 14,419 SANGAMO THERAPEUTICS INC shares in Q2 2022, an estimated $84K.
AlphaCrest Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 9 quarters.
AlphaCrest Capital Management's SANGAMO THERAPEUTICS INC position peaked at $1.24M in Q3 2020.
188 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2022.

Based on AlphaCrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.